Most GLP-1 receptor agonists (except exenatide formulations) carry an FDA boxed warning regarding thyroid C-cell tumors observed in rodent studies and are contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
Cynthia Maxwell MD, MBA, FRCSC, DABOM (Obesity Medicine), is the Medical Content Director of First Exposure, the Vice President, Medical Affairs & System Transformation and Lead Medical Executive at Womens College Hospital and Professor, Faculty of Medicine, Department of Obstetrics and Gynaecology and Division of Maternal Fetal Medicine at the University of Toronto
Mounjaro (tirzepatide) is a dual GIP and GLP-1 receptor agonist licensed in the UK for type 2 diabetes mellitus management
semaglutide, whats the difference
Fasting blood sugar dropped from 6.89 mg/dL to 5.57 mg/dL
These drugs also exhibit additional benefits, such as cardio- and neuroprotection, anti-inflammatory properties, and modulation of reward and food intake behaviors
